JHOS-3

Repurposing Celecoxib for Ovarian Cancer Treatment by Targeting Survivin Signaling

The most common type of reproductive cancer that kills women is ovarian cancer. With a five-year mortality rate just above 45% and high rates of chemo-toxicity and chemo-resistance, it is important to find new treatments that work better and are less harmful. By using ten different types of ovarian cancer cell lines from different histologies, Chuwa et al. wanted to find out if the COX-2 inhibitor celecoxib could help fight tumors.

They discovered that celecoxib can inhibit the growth of all the ovarian cancer cell lines (HTOA, JHOC-7, JHOS-2, JHOS-3, and JHOS-4), which derived from different types of tissue. As shown in Fig. 1, celecoxib effectively and significantly slowed the growth of ovarian cancer cells at IC₅₀ values range from 17µm to 45µm. It has already talked about the genetic changes found in ovarian cancer cell lines. Celecoxib's ability to stop cell growth wasn't linked to or changed by the histological traits or mutational states of these cells. They investigated celecoxib's effect on cell cycle development to learn more about how it inhibits the growth of many types of ovarian cancer cells, no matter what the histology is. The picture in Fig. 2 shows that celecoxib changes the cell cycle by significantly increasing the number of sub-G1 cells (p<0.001, paired t-test) in all cell lines. There was no link between celecoxib's effect on the cell cycle, defects, or the structure of the cells, which suggests that the drug has more than one function.